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Abstract
The use of d-cycloserine (DCS) as a cognitive enhancer to augment exposure-based cognitive-
behavioral therapy (CBT) represents a promising new translational research direction with the 
goal to accelerate and optimize treatment response for anxiety disorders. Some studies suggest that 
DCS may not only augment extinction learning but could also facilitate fear memory 
reconsolidation. Therefore, the effect of DCS may depend on fear levels reported at the end of 
exposure sessions. This paper presents the rationale and design for an ongoing randomized 
controlled trial examining the relative efficacy of tailoring DCS administration based on exposure 
success (i.e. end fear levels) during a 5-session group CBT protocol for social anxiety disorder (n 
= 156). Specifically, tailored post-session DCS administration will be compared against untailored 
post-session DCS, untailored pre-session DCS, and pill placebo in terms of reduction in social 
anxiety symptoms and responder status. In addition, a subset of participants (n = 96) will undergo 
a fear extinction retention experiment prior to the clinical trial in which they will be randomly 
assigned to receive either DCS or placebo prior to extinguishing a conditioned fear. The results 
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from this experimental paradigm will clarify the mechanism of the effects of DCS on exposure 
procedures. This study aims to serve as the first step toward developing an algorithm for the 
personalized use of DCS during CBT for social anxiety disorder, with the ultimate goal of 
optimizing treatment outcome for anxiety disorders.
ClinicalTrials.gov identifier: NCT02066792
Keywords
cognitive-behavioral therapy; exposure therapy; d-cycloserine; social anxiety disorder; social 
phobia
Whereas ample evidence supports the efficacy of cognitive behavioral therapy (CBT) for 
anxiety disorders, response rates leave considerable room for improvement.1 Attempts to 
improve treatment response with combined CBT and anxiolytic pharmacotherapy have led 
to disappointing results.2,3 One promising strategy for strengthening the effects of CBT in 
recent years has been the use pharmacological agents that augment core learning processes 
in CBT. One important element in CBT for anxiety disorders is exposure procedures, which 
rely of extinction learning. Preclinical research has shown that extinction learning is blocked 
by antagonists at the glutametergic N-methyl-D-aspartate (NMDA) receptor, whereas d-
cycloserine (DCS), a partial NMDA agonist, augments such learning in animals (for review, 
see 4).
In clinical settings, a number of studies have shown that DCS also appears to augment the 
effects of exposure therapy (for review, see 5). In one of the first human trials, patients with 
social anxiety disorder (SAD) who received 50 mg of DCS one hour prior to each of five 
exposure sessions had greater reductions in social anxiety symptoms at post-treatment and 
one-month follow-up than those who received exposure therapy plus pill placebo.6 These 
findings were replicated by Guastella and colleagues.7 Similarly promising results were also 
reported in the treatment of height phobia8 and panic disorder.9 In contrast, a number of 
studies have found minimal to no benefits for DCS augmentation of exposure procedures for 
various clinical and subclinical anxiety problems.10–14 In the largest DCS trial to date (n = 
169),12 patients with SAD showed a significantly faster rate of symptom improvement than 
those receiving placebo, but no differences were observed in the response or remission rates 
at post-treatment and 6-month follow-up. In addition to within-session changes, between 
session fear reduction also appears to be of importance, as shown in a recent trial with 156 
Iraq and Afghanistan veterans.15 After six sessions of virtual reality exposure therapy, 
participants showed a greater reduction in PTSD symptoms with d-cycloserine augmentation 
when extinction learning was well achieved between sessions, which was quantified as the 
average decrease in peak subjective distress ratings across successive exposure sessions. 
This effect was not observed when the exposure sessions were combined with alprazolam or 
placebo.
One possible explanation for these inconsistent findings is related to the extent to which 
extinction learning has occurred. Consistent with this hypothesis are the results of a re-
analysis of the study by Hofmann and colleagues.12 The results demonstrated that relative to 
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placebo, patients receiving DCS showed greater symptom improvement at each session 
when self-reported fear levels were low at the end of the prior exposure session.16 
Conversely, patients who received DCS and whose end fear levels were high at the prior 
session showed less symptom improvement than those taking placebo. At post-treatment, 
patients receiving DCS whose average fear level at the end of each exposure was low to 
moderate showed superior outcome to those receiving placebo. Similar results were found in 
another trial with height phobic patients in which DCS was administered post-session.17
It may then be best to selectively administer DCS to patients only after exposures in which 
end fear levels are low, as DCS can make “good” exposures better and “bad” exposure 
worse.18 This is based on findings from animal studies suggesting that NMDA antagonists 
impair reconsolidation of fear memories, whereas DCS appears to enhance reconsolidation 
of fear memory. 19 A critical condition determining whether DCS augments extinction 
learning or reconsolidation appears to be the length of memory reactivation and extinction 
training sessions. If the extinction session (and the period of stimulus re-exposure) is brief, 
reconsolidation processes are dominant, whereas extinction processes dominate in longer 
sessions. 19 Therefore, if fear does not sufficiently decrease during exposure therapy, fear 
memory reconsolidation may occur and DCS can facilitate this counter-therapeutic process. 
To directly test the hypothesis that the success of DCS depends on the level of fear 
experienced at the end an exposure, the present study will examine the effect of selectively 
administering DCS to patients after exposures in which end fear levels are low.
Methods
Study Design and Objectives
This study is funded as a multi-site linked R34 grant (R34MH099318; ClinicalTrials.gov 
identifier: NCT02066792) by the National Institute of Mental Health (Principal 
Investigators: Stefan G. Hofmann, Mark H. Pollack, and Jasper A. J. Smits). The primary 
objective of this study is to optimize the application of DCS as an augmentation strategy for 
exposure therapy. To this end, we will examine the relative efficacy of tailoring post-session 
administration of DCS based on end fear levels during a five-session exposure therapy 
protocol for SAD. Tailored post-session DCS administration will be compared to the most 
common application of DCS in prior research, which is unselective DCS administration 
before exposure sessions, as well as unselective post-session DCS administration in order to 
determine whether post-session DCS administration needs to be tailored. Because results of 
previous trials comparing DCS to placebo have been variable, we will also include a placebo 
condition. We hypothesize that selectively administering DCS when fear levels are low at 
the end of exposures will lead to greater reductions in social anxiety symptoms at post-
treatment and follow-up compared to placebo, unselective pre-session DCS administration, 
and unselective post-session DCS administration.
A secondary aim of this study is to examine whether DCS enhances fear extinction retention 
in a laboratory setting. Doing so will allow us to make inferences about the mechanism of 
action through which DCS enhances outcomes (i.e. whether its effects are due to increased 
fear extinction retention), and to better interpret any possible null results of the clinical trial 
(e.g. DCS may work in an experimental paradigm but not in a clinical setting). To examine 
Hofmann et al. Page 3
Contemp Clin Trials. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
the effect of DCS on fear extinction retention, a subset of participants will complete a 
computerized protocol involving a fear conditioning procedure, fear extinction training, and 
fear extinction retention testing on three separate days, while receiving DCS or pill placebo 
prior to extinction training. We hypothesize that participants receiving DCS will show 
greater fear extinction retention in the laboratory experiment than those receiving placebo.
Participants
Our sample will consist of 156 participants for the clinical trial portion of the study, with a 
subset of 96 participants completing the optional laboratory-based fear extinction paradigm. 
Recruitment, which began January 2015 and is expected to continue through the end of 
2017, will be split equally amongst the three study sites: Boston University, University of 
Texas at Austin, and Rush University Medical Center in Chicago. Inclusion criteria include 
(1) a primary diagnosis of SAD as defined by DSM-5 criteria.20 (2) A total score > 60 on the 
Liebowitz Social Anxiety Scale (LSAS).21 (3) At least 18 years of age. (4) A physical 
examination and laboratory findings without clinically significant abnormalities. (5) 
Willingness and ability to provide informed consent and comply with the requirements of 
the study protocol.
Exclusion criteria include: (1) A lifetime history of bipolar or psychotic disorders or 
obsessive-compulsive disorder; an eating disorder, PTSD, or substance abuse or dependence 
(other than nicotine) in the past 6 months; organic brain syndrome, mental retardation or 
other potentially interfering cognitive dysfunction. (2) Significant suicidal ideation or 
suicidal behaviors within 6 months prior to intake. (3) Concurrent psychotropic medication 
(e.g., antidepressants, anxiolytics, beta blockers) within the 2 weeks prior to initiation of 
treatment. (4) Significant personality dysfunction likely to interfere with study participation 
(e.g., being overly aggressive or abusive towards the therapists or group members). (5) 
Serious medical illness or instability for which hospitalization may be likely within the next 
year. (6) A history of seizures. (7) Pregnant women, lactating women, and women of 
childbearing potential who are not using medically accepted forms of contraception. (8) 
Concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy 
of any duration directed specifically toward treatment of the SAD. (9) Prior non-response to 
adequately-delivered exposure therapy. (10) A history of head trauma causing loss of 
consciousness, seizure or ongoing cognitive impairment.
Screening and Randomization
Individuals interested in the study will undergo a psychiatric evaluation consisting of a 
diagnostic clinical interview and an administration of the LSAS to evaluate psychiatric 
inclusion and exclusion criteria. Participants will also be medically cleared by a study 
physician.
Participants in the optional fear extinction retention experiment will be randomized to 
receive either DCS or placebo prior to fear extinction procedures. For the clinical trial 
portion of the study, participants will be randomized to one of four conditions: 1) tailored 
post-session DCS, 2) unselective pre-session DCS, 3) unselective post-session DCS, or 4) 
pill placebo. The conditions of the fear extinction experiment will be equally distributed 
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across the four clinical trial conditions such that participants will be equally likely to receive 
any combination of fear extinction condition and trial condition. Randomization will occur 
by site using variable-sized permuted block randomization (block sizes varying from 4 to 
12). Randomization tables will be created before the first subject is run and sent to the study 
pharmacist to make the appropriate medication kits. Prior to data analysis, the project 
statistician will check the balance of randomization to control for any unbalanced factors.
Fear Extinction Retention Experiment
The fear extinction retention experiment will occur on three separate days prior to the 
initiation of therapy. Participants who partake in this portion of the study will undergo 
conditioning procedures on Day 1, extinction learning on Day 2, and extinction recall and 
fear renewal on Day 3 (see figure 1). Day 1 and Day 3 sessions will take place no more than 
seven days apart, and ideally sessions will occur on consecutive days. DCS or placebo will 
be administered immediately prior to the Day 2 procedures to examine whether DCS 
enhances extinction recall and reduces fear renewal on Day 3.
The procedures for this experiment are based off a previously validated fear conditioning 
and extinction paradigm.22 During each portion of the experiment, recording electrodes will 
be attached to the palm of the participant’s left hand to measure skin conductance response 
(SCR), and stimulating electrodes will be connected to two fingers of the participant’s right 
hand to deliver an electric shock. SCR will be measured through a 9-mm (sensor diameter) 
Sensor Medics Ag/AgCl electrodes. For each trial, participants will view a computer 
monitor with an image of one of two different rooms containing an unlit lamp for 6 seconds. 
The lamp will then be “switched on” to one of two colors for 12 seconds, which will serve 
as the conditioned stimulus (CS). One of the two colors will be paired with an electric shock 
(the unconditioned stimulus, or US), while the other color will not. The shock will have 
been previously selected by the participant to be “highly annoying but not painful” and 
delivered for 500 millisecond through electrodes attached to the second and third finger of 
the right hand. The inter-trial interval will last between 12 and 18 seconds, with an average 
of 15 seconds. The stimulating electrodes will remain attached to the fingertips throughout 
all three days of the experiment, but the US will be administered only during the 
Conditioning session on Day 1.
On Day 1, the to-be CS+ and the to-be CS− (four trials of each) will be presented within 
each room in a counterbalanced manner without presentation of the US (Habituation phase). 
The Conditioning phase will follow with five CS+ trials that will be immediately followed 
by the US (100% reinforcement), and five CS− trials (i.e., not followed by shock). All 
conditioning trials will use the same context (one of the two rooms). On Day 2 (Extinction 
phase), five CS+ trials and five CS− trials will be presented within the extinction context 
(the room not used during conditioning) with no US presentation. Day 3 consists of the 
Extinction Recall phase and the Renewal phase. Extinction Recall is identical to the 
Extinction phase on day 2, while Renewal is identical to the Conditioning phase except 
without presentation of the US. Upon completion of each day of the fear extinction retention 
experiment participants will be compensated $40 (i.e., $120 total).
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For each trial, SCR will be calculated by taking the difference between the highest skin 
conductance level (SCL) during each 12-second CS+/CS− presentation and the mean SCL 
during the 2 seconds immediately preceding that trial. The SCR for the CS− will be 
subtracted from the SCR for the CS+ to create a differential SCR. Performance during 
Extinction Training and Recall will be assessed by comparing SCR during CS+ trials on 
Day 2 and 3 with the maximum SCR during the Conditioning phase. Our main outcome of 
interest will be Extinction Retention, for which we will calculate an extinction retention 
index based on the ratio of the mean SCR during the first two trials of the Extinction Recall 
phase to the largest SCR during the Day 1 Conditioning phase. This ratio will be multiplied 
by 100 to yield a percentage of the maximum conditioned response, and this value will be 
subtracted from 100% to yield the extinction retention index.
Therapy Procedures
Consistent with prior clinical trials examining DCS for SAD,6,7 we will use a 5-session 
group CBT protocol emphasizing repeated exposure practice. Each group will consist of 4–6 
patients and 2 therapists, who will be PhDs or advanced, trained doctoral students 
supervised by the first and fifth authors. In the first session (60 minutes), patients will be 
introduced to the cognitive-behavioral model of SAD and provided a rationale for treatment 
with exposure therapy. Sessions 2–5 (90 minutes each) will consist of increasingly difficult 
public speaking exposure tasks in which each participant in the group will give an 
impromptu speech on a topic chosen by the therapist in front of the other group members, 
confederates and a video camera. Video recordings of each exposure will then be reviewed, 
and participants will compare pre-exposure predictions about their behavior and appearance 
during the speech task with their actual performance. At the conclusion of each exposure 
session, patients will be encouraged to continue to apply home-practice strategies (such as 
giving speeches in front of a mirror). Continued practice of the interventions will be 
considered part of treatment, and patients will be asked to refrain from alternative treatment 
for four weeks following completion of the last treatment session.
Pill Administration
Following prior research demonstrating DCS to augment the efficacy of exposure 
therapy,6–9 DCS will be administered in 50 mg doses. Administration of DCS at such a dose 
has been shown to have a benign side effect profile,23,24 and increasing the dose to as high 
as 500 mg has not been shown to produce an additive effect in enhancing exposure-based 
treatment.8 Study capsules containing DCS and placebo will be identical in appearance, and 
will be administered by study staff blind to study condition and not involved in the 
assessment or treatment of study participants. Participants who elect to undergo the fear 
extinction retention experiment will take one study pill of either 50 mg DCS or placebo 
immediately before Day 2 of the experiment.
For the clinical trial, the pharmacist will fill three bottles (with one pill type in each) for 
each patient for each exposure session according to the schedule in Table 1. Patient, 
therapist, and a staff member will be blind to the drug condition (DSC vs. placebo) at pre-
exposure; and therapists and patients will be blind to the drug condition at post-exposure. 
Regardless of study condition, research staff will administer a pill (Pill 1) to each participant 
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one-hour before the exposure session and administer a second pill (Pill 2) immediately after 
the exposure session. In the tailored administration condition, the selection of Pill 2 will be 
guided by the end fear level. Specifically, DCS will be administered by the research staff if 
the end fear is ≤40 (of 100) on the Subjective Units of Distress Scale (SUDS), whereas 
placebo will be selected if the end fear is >40. A cutoff of 40 and below was selected based 
on results of our prior clinical trial, which demonstrated that when end SUDS ratings were 
below 47, DCS showed an advantage over placebo.16 Two prior studies using the same 5-
session CBT protocol found that mean end SUDS ratings were 49.5 (SD = 19.2)12 and 39.1 
(SD = 17.7).25 In the latter study, 85% of patients had at least one end SUDS rating of 40 or 
below, and 67.5% had at least 2 end SUDS ratings of 40 or below, demonstrating that there 
is sufficient variability in end fear ratings to justify the examination of tailored and non-
tailored post-session DCS administration.
Primary Outcome Measures
The timing of the administration of assessments is detailed in Table 2. Clinician-
administered instruments (LSAS, SPD-SC Form and MADRS) will be delivered by trained 
independent evaluators who are blind to treatment condition.
Liebowitz Social Anxiety Scale (LSAS)—The Liebowitz Social Anxiety Scale21 is a 
24-item clinician-administered scale that assesses fear and avoidance in social and 
performance situations within the last week. Fear and avoidance are rated separately on a 
scale ranging from 0 (no fear/never avoids) to 3 (severe fear/usually avoids), and ratings are 
combined to form a total score (range 0 – 144). The instrument is widely used in social 
anxiety treatment studies and shows very good psychometric properties.26,27
Social Phobic Disorders Severity and Change Form (SPD-SC Form)—The 
Social Phobic Disorders Severity and Change Form28 is an expansion and adaptation of the 
Clinical Global Impression Scale (CGI)29 for social anxiety disorder. Similar to the original 
CGI scale, the SPD-SC Form is rated on a 7-point scale to indicate severity and 
improvement. We chose this scale over the original CGI scale because it provides a more 
detailed analysis of psychological functioning for individuals with SAD. Furthermore, past 
social anxiety treatment studies12,30 have used the SPD-SC Form rather than the CGI.
Secondary Outcome Measures
Appraisal of Social Concerns (ASC)—The Appraisal of Social Concerns measure31 is 
a 20-item self-report questionnaire that assesses concern regarding potential outcomes of 
social situations that are commonly feared among socially anxious individuals. The types of 
concerns measured by the ASC load on to three factors: negative evaluation (e.g. “appearing 
stupid”), observable symptoms (e.g. “trembling”) and social helplessness (e.g. “people 
ignoring you”). Each potential outcome is rated in terms of amount of concern on a 0–100 
scale (in increments of 10) with the following anchors: 0=Not at all concerned, 20=Mildly 
concerned, 50=Moderately concerned, 80=Very concerned, and 100=Extremely concerned. 
Data from both clinical and nonclinical samples have indicated that the ASC has very good 
psychometric properties.31
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Subtle Avoidance Frequency Examination (SAFE)—The Subtle Avoidance 
Frequency Examination32 measures safety behaviors that people with social anxiety 
typically engage in as a way of diminishing anxiety. The SAFE is a 32-item self-report 
scored on a Likert scale from 1 to 5, with a score of 1 indicating that the individual “Never” 
engages in the behavior and a score of 5 indicating that the individual “Always” engages in 
the behavior. This measure has three factors: active safety behaviors (e.g. “rehearsing 
sentences in your mind”), subtle restriction of behavior (e.g. “remain silent”), and behaviors 
aimed at avoiding or concealing physical symptoms (e.g. “say ‘it’s hot’ to explain sweating 
or blushing”). The SAFE has been shown to have excellent psychometric properties, the 
ability to distinguish between clinical and nonclinical populations, and is able to 
successfully assess treatment outcome.32
Social Anxiety Questionnaire for Adults (SAQ)—The Social Anxiety Questionnaire 
for Adults33 is a 30-item self-report measure that assesses the level of unease, stress, or 
nervousness experienced during different social situations. The SAQ assesses five 
dimensions of social anxiety that are considered not well addressed in extant measures of 
social anxiety. These dimensions are 1) interactions with strangers, 2) speaking in public/
talking with people in authority, 3) interactions with the opposite sex, 4) criticism and 
embarrassment, and 5) assertive expression of annoyance, disgust, or displeasure. Items are 
rated on a 5-point Likert scale ranging from 1 (no unease, stress, or nervousness) to 5 (very 
high or extreme unease, stress, or nervousness). The measure demonstrates excellent 
psychometric properties.33
Montgomery Asberg Depression Rating Scale (MADRS)—The Montgomery 
Asberg Depression Rating Scale34 is a clinician-administered measure designed to assess 
overall severity of depressive symptoms. The MADRS consists of 10 symptoms of 
depression rated on a scale from 0 to 6, with anchors specific to each item. It has 
demonstrated good reliability, specificity for symptoms of depressive compared to anxiety, 
and sensitivity to change during treatment.34 The MADRS will be used to assess depression 
both as a secondary outcome and as a potential treatment moderator.
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)—The 
Quality of Life Enjoyment and Satisfaction Questionnaire35 is a questionnaire rating 16 
aspects of quality of life, including physical health, mood, activities of daily living, and 
overall life satisfaction. The Q-LES-Q has been shown to be a valid and reliable instrument 
that measures a construct related to but distinct from severity of illness.35
Measures of Exposures Success
Subjective Units of Distress Scale (SUDS)—Participants will provide fear ratings at 
the beginning of an exposure exercise (i.e., Beginning Fear) and just prior to the conclusion 
of an exposure exercise (i.e., End Fear). In addition, after the exercise they will indicate their 
highest level of fear experienced during exposure (i.e., Peak Fear). Fear ratings will be 
assessed using the subjective units of distress scale (SUDS),36 which ranges from 0 to 100 
(0=no fear, relaxed; 25=mild fear, able to cope; 50=moderate fear, trouble concentrating; 
75=severe fear, thoughts of leaving; 100=very severe fear, worst ever experienced). The 
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procedures for collecting fear ratings will be similar to that in previous social anxiety 
disorder treatment studies from our group and other groups.16,37–40 Specifically, during the 
first session, therapists will introduce patients to the SUDS as they work together to develop 
a fear and avoidance hierarchy. Attention will be given to the anchors such that patients can 
distinguish the different levels along the scale. Accordingly, by the time patients initiate 
exposure practice (i.e., session 2), they will have had had ample practice using the scale. We 
will use a fear rating at the end of exposure of ≤40 as an index of exposure success (see 
Table 1).
Heart Rate—In addition to providing SUDS ratings, participants will also wear a Polar 
heart rate monitoring watch and chest band during the exposure exercise during sessions 2 
through 5 as a secondary, physiological measure of anxiety within the session. A sweatband 
will be placed over the watch so that participants will not see their heart rate during the 
exposure (as this could be a distraction). Maximum and average heart rate will be recorded 
over the course of the exposure, and compared to baseline heart rate at the start of the 
session.
Salivary Samples—Saliva will be collected and assayed for salivary cortisol (ng/mL) and 
salivary alpha amylase (U/ml) using a highly sensitive enzyme immunoassay. Patients will 
be asked not to brush their teeth, eat, drink or smoke 30 minutes prior to collection of saliva 
samples. Saliva samples of 0.5ml will be collected prior to and directly after the first and last 
exposure tasks, sessions two and five respectively. The post-exposure amylase salivary 
samples will be collected within five minutes of the end of the exposure, while the post-
exposure cortisol level will be collected twenty minutes post exposure. Saliva samples will 
be frozen at −80°C and be sent frozen to a central processing laboratory at the conclusion of 
enrollment. We will use cortisol and alpha amylase levels as additional indicators of the 
stress response to exposure. Specifically we will investigate the relationship between these 
indicators and heart rate and SUDS levels, and as a moderator of the relationship between 
DCS and treatment outcome.
Potential Moderators and Predictors
Pittsburgh Sleep Quality Index (PSQI)—The PSQI is a well-validated self-report 
instrument that assesses sleep quality over the past month.41 The measure consists of seven 
items rated on a 4-point scale: subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime 
dysfunction. These items are summed to create a global PSQI score with higher scores 
reflecting poorer sleep quality (range 0–21). The use of the PSQI at baseline is based on 
prior research that found poorer baseline sleep to predict worse treatment outcome during 
CBT for SAD.42
Consensus Sleep Diary (CSD)—The Consensus Sleep Diary was developed amongst a 
collaboration of insomnia experts in order to create a standardized assessment of nightly 
sleep quality.43 The core CSD contains 9 consensus-determined critical parameters of sleep 
related to the time of day one goes to bed and gets up, and the duration and quality of sleep. 
The CSD will be administered the night before and after each session based on researching 
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showing that that higher levels of restorative sleep the night following an exposure session 
predicted lower social anxiety symptoms at the next session.42 Post-session sleep may then 
affect the consolidation of in-session learning, and will be explored as a moderator of the 
relationship between in-session learning (i.e. fear reduction) and treatment outcome.
NEO-Five-Factor Inventory—At the baseline session, participants will complete the 60-
item NEO-Five-Factor Inventory (NEO-FFI),44 which is a psychometrically-sound measure 
of the five traits from the Five-Factor model of personality: agreeableness, 
conscientiousness, extraversion, neuroticism, and openness. Using the NEO-FFI will enable 
this study to potentially replicate prior research that found DCS augmentation to be more 
effective in SAD for individuals who score low in conscientiousness and high in 
agreeableness.38
Analysis of audio-recorded speech—The speech delivered in session 2 (the first 
exposure session) will be audio recorded and saved for later analysis (including analysis of 
vocal tone and content). For vocal analyses, these recordings will be analyzed using 
methodology similar to that used in recent studies,45 which involves taking selections of 
speech and using an audio analyzer to examine audio properties such as pitch, frequency, 
and silences. The speeches will also be transcribed for content analysis using a software 
program called the Linguistic Inquiry and Word Count (LIWC), which computes 
percentages of words that fall into various categories.46
Clinical Characteristics—Baseline psychiatric functioning will be assessed by clinician-
rated measures. This domain comprises clinical severity as assessed by the Social Phobic 
Disorders Severity Form; (SPD-SC),28 depressive symptom severity as assessed by the 
MADRS,34 Axis I comorbidity (i.e., number of comorbid Axis I disorders) as well as history 
of antidepressant and other psychotropic medication use. There is some evidence to suggest 
that antidepressants interact with DSC to block its augmentation effect on fear extinction.47 
Therefore, consistent with our earlier trial12 we decided to exclude participants with 
concurrent psychotropic medication use. Our experience with this earlier trial indicates that 
this exclusion criterion is unlikely to negatively affect recruitment or generalizability of the 
findings. Comorbidity and medication use will be assessed with the Structured Clinical 
Interview (SCID)48 or the Anxiety and Related Disorders Interview Schedule for DSM-5 
(ADIS-5).49
Credibility and Expectancy—The Credibility/Expectancy Questionnaire (CEQ) is a 
widely used 6-item measure assesses treatment credibility and expectancy.50 Credibility is 
thought to be a cognitive assessment of the rationale for treatment, while expectancy is an 
affectively-based belief about the likelihood of success in treatment. The CEQ has 
demonstrated high internal consistency within each of the credibility and expectancy and 
good test-retest reliability.50
Patient Adherence—Patient adherence to each intervention will be assessed as the 
number of total sessions attended.
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Safety Monitoring
A review of medical history, a physical examination, and laboratory tests will be performed 
at admission, and vital signs measured at the baseline visit. Patients with clinically 
significant abnormalities in vital signs (e.g., systolic blood pressure >150 mm Hg or 
diastolic blood pressure<50 mm Hg) at baseline will be excluded from further study 
participation and referred for appropriate clinical management. Pregnancy tests for all 
female participants of childbearing potential will be administered at intake and each month 
following randomization. Patients will be queried at each visit regarding the presence of 
adverse effects associated with the study medication. On Day 2 of the Fear Extinction 
Experiment and at each of the four study visits during which participants are asked to take 
study medication, participants will be asked to breathe into an AlcoBreath tube in order to 
assess for the presence of alcohol before they are administered the study medication.
Data Analysis
We will assess the equivalence of the treatment groups on key baseline variables 
(demographics and psychological variables), and any variables that differ among groups will 
be used as covariates in the final analyses. We will then examine missing data patterns, 
dropout rates, and distributional properties of measures and use transformations to improve 
distributions if necessary. We will use pattern mixture modeling to assess the effect of 
missing data.51 We will rerun our analyses coding for various missing data patterns (no 
missing data, sporadic missing, dropouts, etc.) to determine 1) if missingness impacts our 
findings and 2) how the differences between treatment conditions depends on the missing 
data pattern.
We will use multilevel modeling (MLM) to evaluate the effect of condition on our 
continuous outcome measures (LSAS, SPD-SC severity, MADRS, QLES-Q) and 
generalized linear mixed modeling (GLMM, which is MLM with a logistic linking function) 
to examine DCS’s effect on the dichotomous outcomes (“response” and “remission,” 
explained below). MLM is the recommended method for analyzing longitudinal psychiatric 
data,52 easily accommodates missing data, and allows inclusion of all subjects in the 
analysis even if they drop out. In our MLM analyses, the repeated assessments over time 
will be nested within individuals, which will be nested within treatment cohort, thereby 
appropriately accounting for correlated scores within cohorts. We will use a piecewise 
growth curve model, separately modeling change over time during treatment and follow-up. 
Although our prior large DCS study12 found each “piece” of the growth curve to be linear, 
we will test for quadratic trends and include them if significant. Other non-linear models 
(e.g., exponential models) will be also be tested, and the model that best fits the data (based 
on AIC and BIC) will be used. Our “time” variable in these models will be coded as 
“assessment week” and will reflect the number of weeks since baseline. Using this model, 
we can test differences between tailored DCS administration and the 3 comparison groups 
(pre-session DCS, post-session DCS, and placebo) by including 3 dummy coded variables as 
predictors of the growth curve parameters. Each dummy variable will contrast tailored DCS 
to each of the other 3 conditions.
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Definition of Treatment Response and Remission
The definition of treatment “response” is based on the SPD-SC and is defined by an overall 
change score of 2 (much improved) or 1 (very much improved) as compared to the pre-
treatment assessment. “Remission” is defined as an SPD-SC of 2 or 1 and an LSAS total 
score of < 30. This LSAS cutoff score is supported by a study of 364 patients that used 
receiver-operating characteristics in diagnosing SAD,53 and has generally been adopted as 
the boundary between remitted and symptomatic patients.54 It should be noted that the goal 
of this study is to determine effect size estimates for these gold-standard response and 
remission outcomes. Detecting differences on these dichotomous outcomes would require a 
very large sample size, and thus these estimates will be used to evaluate whether a larger-
scale trial is warranted.
Outcome Analysis
In order to evaluate whether tailored DCS administration produces superior outcomes to pre-
session DCS, post-session DCS, and placebo, we will examine if the dummy variable 
contrasting tailored DCS to the relevant comparison condition is a significant predictor of 
the intercept. We will alternately “center” the “assessment week” variable at either 
posttreatment, 1-mo FU, or 3-mo FU to test for significant differences between conditions at 
each of these time points.55
We will also examine a number of possible moderators (demographic, clinical, and 
personality variables) of the potential superiority of tailored DCS over the comparison 
conditions (and, secondarily, of the superiority of pre-and post-DCS administration over 
PBO). We will use the Fournier approach56 to identify important moderators. This approach 
uses an algorithmic method to select significant predictors and moderators within each 
group of potential moderators (the groups being demographics, clinical characteristics, 
personality variables). These selected moderators are then combined in a final analysis, 
which identifies moderators that are significant over and above the other potential 
moderators. This approach strikes a balance between testing each moderator separately 
(which substantially increases Type I error due to the multiple tests) and testing all 
moderators simultaneously (which may substantially increase the likelihood of Type II 
error). We have successfully used this approach to examining the moderators of pre-session 
administration of DCS.38
Power analysis
As mentioned above, the primary goals of this study are to 1) determine the efficacy of 
tailored DCS administration and 2) determine whether a larger scale trial is warranted. As a 
result, this study is not powered to detect small differences between treatment conditions, 
nor is it powered to detect differences on our dichotomous outcomes. Accordingly, we 
performed power analyses only for our primary outcomes, which were continuous measures 
of LSAS and SPD-SC. MLM allows the inclusion of all subjects with at least one data point, 
regardless of missing data and regardless of whether they drop out. Thus, we based our 
power analysis on 156 participants and conservatively assumed that, on average, we will 
obtain 5 out of the 7 total assessments from each subject. The power analyses were 
calculated using the program PinT 2.12 (Power in Two Level Models).57
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For our main outcome analysis, we used our similarly sized DCS trial12 to estimate the 
variances and covariances required by PinT, and calculated detectable effect sizes for both 
LSAS and SPD-SC. PinT indicated we would have a power of .80 to detect an effect size as 
low as d=.296, between a small (d=.20) and a medium (d=.50) effect size. This translates 
into a difference of 6.59 points on the LSAS and .42 points on the SPD-SC (at post-
treatment, 1-month follow-up, or 3-month follow-up). For the Fournier moderator analysis, 
we assumed five simultaneous moderators in each group, and included their 15 interactions 
with the 3 dummy variable contrasts. Moderators were modeled as predictors of both the 
intercept and slope. Again using our prior DCS study to calculate the variances and 
covariances required by PiNT, we found that, with .80 power, we could detect an effect size 
of d=.466, slightly smaller than a medium effect size.
Discussion
This study aims to serve as the first step toward developing an algorithm for personalizing 
the use of DCS in CBT for anxiety, with the ultimate goal of maximizing the efficacy and 
cost-effectiveness of the treatment of anxiety disorders. Although prior clinical trials 
examining DCS as an augmentation strategy for exposure therapy have shown mixed 
results,6,12 recent findings suggest that the effect of DCS depends on the success of exposure 
sessions.15,16 Following such research, as well as evidence suggesting that DCS might 
facilitate fear memory reconsolidation if fear does not sufficiently decrease during exposure 
therapy,19 the present study will test the relative efficacy of tailoring DCS administration 
based on end fear levels as a strategy for optimizing treatment outcome. Specifically, we 
will compare tailored post-session DCS administration with untailored pre-session DCS 
administration, untailored post-session DCS administration, and pill placebo in the context 
of a 5-session CBT protocol for SAD. The results from this trial will add to the body of 
research examining the extent to which DCS can enhance exposure-based CBT for anxiety, 
and also illuminate the optimal use of DCS in the context of CBT.
Beyond examining the efficacy of different DCS administration strategies, this study will 
contribute to our understanding of the use of the DCS and CBT for anxiety disorders in a 
number of additional ways. For one, we will use an experimental fear extinction retention 
paradigm to help clarify the mechanism through which DCS might enhance treatment 
outcome in this study. By testing the effect of DCS on fear extinction retention in a 
laboratory setting with a subset of participants in the clinical trial, this study has the 
potential to make a strong claim that DCS is efficacious in a clinical setting because it 
enhances fear extinction retention (the purported mechanism). On the other hand, this 
experiment could also help clarify results if the findings from trial are null, as we will know 
whether DCS had any impact on extinction retention in the context of laboratory 
conditioning paradigm. A relative limitation, however, is that clinical fear and de novo 
conditioned fears in humans may not similarly engage fear networks,58 hence dissociation in 
results between these paradigms may further clarify the role of de novo fear conditioning as 
a model for clinical fears.
This study embodies the goals of personalized medicine by examining tailored use of DCS 
and by investigating a number of potential predictors and moderators of the effect of CBT 
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and DCS on social anxiety. Specifically, the impact of sleep quality on the relationship 
between in-session learning and symptom reduction will be tested as a way of understanding 
a potential factor that could interfere with treatment success. Physiological measures 
including heart rate, salivary cortisol and alpha amylase will also be investigated as potential 
moderators of the impact of DCS on treatment outcome, and as correlates of subjective 
distress ratings.
The use of DCS in conjunction with CBT represents an innovative approach toward 
maximizing psychotherapy treatment outcomes. Rather than directly targeting anxiety 
symptoms themselves, DCS enhances symptom reduction by augmenting the learning 
processes involved in exposure therapy. This line of research results from a promising 
translation of research on fear extinction from preclinical neuroscience to clinical settings, 
but clinical research on DCS augmentation thus far demonstrates that the application of DCS 
to clinical settings requires further refinement. The present study aims to test one such 
refinement by comparing the effects of tailored DCS administration (based on exposure 
success) with administration strategies used in prior research (untailored pre- and post-
session administration). This research is a step toward precision medicine that could lead to 
an algorithm for personalized DCS administration during exposure therapy, thereby 
optimizing treatment outcomes for anxiety disorders and significantly reducing the 
enormous suffering and disability caused by pathological anxiety.
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Figure 1. 
Schematic depiction of the fear extinction retention paradigm. In each phase, participants 
view a computer monitor with an image of a room containing an unlit lamp for 6 seconds. 
The lamp then lights up to one of two colors for 12 seconds. During conditioning, one color 
of the lamp (CS+) is paired with a 500 ms electric shock in context 1. During extinction 
training, the CS+ is presented in context 2 without the US, as is the CS- (not shown). This 
procedure is repeated in context 2 during extinction recall, and in context 1 during renewal.
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Table 1
Pill administration schedule
Condition Pre-exposure (1st Pill ) Post-exposure (2nd Pill)
If SUDS ≤ 40 If SUDS > 40
1. Pre-session DCS DCS PBO PBO
2. Placebo PBO PBO PBO
3. Non-tailored post-session DCS PBO DCS DCS
4. Tailored administration PBO DCS PBO
Note: The Table shows the pill administration schedule. All patients receive 2 pills, one before and one after the exposure session. Depending on 
experimental condition and SUDS at end of exposure, patients receive one of 4 pill combinations. SUDS: Subjective Units of Distress Scale (rated 
1–100); PBO: placebo; DCS: D-cylcoserine (50 mg).
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in
at
io
n;
 S
A
Q 
= S
oc
ial
 A
nx
iet
y Q
ue
sti
on
na
ire
 fo
r A
du
lts
; M
AD
RS
 = 
M
on
tgo
me
ry 
As
be
rg 
De
pre
ssi
on
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R
at
in
g 
Sc
al
e;
 Q
-L
ES
-Q
 = 
Qu
ali
ty 
of 
Li
fe 
En
joy
me
nt 
an
d S
ati
sfa
cti
on
 Q
ue
sti
on
na
ire
; P
SQ
I =
 Pi
tts
bu
rgh
 Sl
eep
 Q
ua
lity
 In
de
x; 
CS
D 
= C
on
sen
sus
 Sl
eep
 D
iar
y. 
SU
DS
 = 
Su
bje
cti
ve
 U
nit
s o
f D
ist
res
s S
cal
e; 
N
EO
-F
FI
 =
 N
EO
 F
iv
e 
Fa
ct
or
 In
ve
nt
or
y 
of
 P
er
so
na
lit
y;
 C
EQ
 = 
Cr
ed
ibi
lity
 an
d E
xp
ec
tan
cy
 Q
ue
sti
on
na
ire
.
a
Th
e 
fe
ar
 e
xt
in
ct
io
n 
ex
pe
rim
en
t w
ill
 b
e 
sc
he
du
le
d 
af
te
r p
ar
tic
ip
an
ts 
ar
e 
de
em
ed
 e
lig
ib
le
 fr
om
 th
e 
A
D
IS
/S
CI
D
 a
nd
 m
ed
ic
al
 e
xa
m
in
at
io
n.
b I
nd
ic
at
or
s o
f e
xp
os
ur
e 
su
cc
es
s a
re
 m
ea
su
re
d 
du
rin
g 
se
ss
io
ns
 2
–5
 o
nl
y,
 an
d 
sa
liv
ar
y 
co
rti
so
l a
nd
 al
ph
a a
m
yl
as
e s
am
pl
es
 w
ill
 b
e c
ol
le
ct
ed
 at
 se
ss
io
ns
 2
 an
d 
5 
on
ly
.
c S
ub
jec
ts 
wi
ll c
om
ple
te 
the
 C
SD
 th
e n
igh
t b
efo
re 
an
d t
he
 ni
gh
t a
fte
r e
ach
 se
ssi
on
.
d R
ec
or
di
ng
s o
f s
pe
ec
he
s f
ro
m
 se
ss
io
n 
2 
on
ly
 w
ill
 b
e 
sa
ve
d 
fo
r f
ur
th
er
 a
na
ly
sis
.
e T
he
 C
EQ
 w
ill 
be
 ad
mi
nis
ter
ed
 af
ter
 th
e f
irs
t s
ess
ion
 on
ly.
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